Dieckmann, Linda http://orcid.org/0000-0002-1050-0098
Cruceanu, Cristiana
Lahti-Pulkkinen, Marius
Lahti, Jari
Kvist, Tuomas
Laivuori, Hannele
Sammallahti, Sara
Villa, Pia M.
Suomalainen-König, Sanna
Rancourt, Rebecca C.
Plagemann, Andreas
Henrich, Wolfgang
Eriksson, Johan G.
Kajantie, Eero
Entringer, Sonja
Braun, Thorsten
Räikkönen, Katri
Binder, Elisabeth B.
Czamara, Darina
Funding for this research was provided by:
Academy of Finland (1284859, 12848591, 312670, 1324596, 311617, 269925, 1312670, 128789, 1287891)
Max Planck Institute of Psychiatry
Article History
Received: 25 August 2021
Revised: 24 November 2021
Accepted: 13 December 2021
First Online: 3 February 2022
Declarations
:
: EB is the coinventor of FKBP5: a novel target for antidepressant therapy, European Patent no. EP 1687443 B1, and receives a research grant from Böhringer Ingelheim for a collaboration on functional investigations of FKBP5. Otherwise, the authors declare that they have no competing interests.
: The ITU research protocol has been approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District (approval date: 06.01.2015, reference number: 269/13/03/00/09). The PREDO study protocol was approved by the Ethics Committee of Obstetrics and Gynaecology and Women, Children and Psychiatry of the Helsinki and Uusimaa Hospital District and by the participating hospitals. The BET study was approved by the Ethics Committee of the Charité-Universitätsmedizin, Berlin, Germany (EA2-149-07). In all studies, participants signed a written informed consent form.